-=Chemours (CC) reported earnings on Thur 13 Feb 20 (a/h)

• Feb. 11:  #1, 5, 6, 52, 95; vol. 1.8M  -> 23%

Chemours beats by $0.11, beats on revs; guides FY20 EPS in-line

Reports Q4 (Dec) earnings of $0.56 per share, $0.11 better than the S&P Capital IQ Consensus of $0.45; revenues fell 4.4% year/year to $1.4 bln vs the $1.37 bln S&P Capital IQ Consensus.

Co issues in-line guidance for FY20, sees EPS of $2.60-$3.55 vs. $3.22 S&P Capital IQ Consensus. Capital expenditures are expected to be approximately $400 mln, with Free Cash Flow of greater than $350 mln.

Commentary: "Our outlook for 2020 reflects top line and bottom line growth across all segments. While the macroeconomic environment remains uncertain, we remain committed to delivering solid earnings growth and a significant improvement in free cash flow."